

## DAFTAR PUSTAKA

- [1] F. Bray, M. Laversanne, H. Sung, J. Ferlay, R. L. Siegel, I. Soerjomataram, and A. Jemal, “Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA: A Cancer Journal for Clinicians*, vol. 74, pp. 229–263, 5 2024. [Online]. Available: <https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834>
- [2] R. M. Hoffman, F. D. Gilliland, J. W. Eley, L. C. Harlan, R. A. Stephenson, J. L. Stanford, P. C. Albertson, A. S. Hamilton, W. C. Hunt, and A. L. Potosky, “Racial and ethnic differences in advanced-stage prostate cancer: The prostate cancer outcomes study,” *Journal of the National Cancer Institute*, vol. 93, pp. 388–395, 3 2001. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/11238701/>
- [3] R. J. Rebello, C. Oing, K. E. Knudsen, S. Loeb, D. C. Johnson, R. E. Reiter, S. Gillessen, T. V. der Kwast, and R. G. Bristow, “Prostate cancer,” *Nature Reviews Disease Primers* 2021 7:1, vol. 7, pp. 1–27, 2 2021. [Online]. Available: <https://www.nature.com/articles/s41572-020-00243-0>
- [4] D. Ilic, M. Djulbegovic, J. H. Jung, E. C. Hwang, Q. Zhou, A. Cleves, T. Agoritsas, and P. Dahm, “Prostate cancer screening with prostate-specific antigen (psa) test: a systematic review and meta-analysis,” *BMJ (Clinical research ed.)*, vol. 362, 2018. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/30185521/>
- [5] S. W. Merriel, L. Pocock, E. Gilbert, S. Creavin, F. M. Walter, A. Spencer, and W. Hamilton, “Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (psa) for the detection of prostate cancer in symptomatic patients,” *BMC Medicine*, vol. 20, pp. 1–11, 12 2022. [Online]. Available: <https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02230-y>
- [6] A. Matsukawa, T. Yanagisawa, K. Bekku, M. K. Parizi, E. Laukhtina, J. Klemm, S. Chiujdea, K. Mori, S. Kimura, T. Fazekas, M. Miszczyk, J. Miki, T. Kimura, P. I. Karakiewicz, P. Rajwa, and S. F. Shariat, “Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: A systematic review and meta-analysis,” *European Urology Oncology*, vol. 7, pp. 697–704, 8 2024.
- [7] M. Ahdoott, A. R. Wilbur, S. E. Reese, A. H. Lebastchi, S. Mehralivand, P. T. Gomella, J. Bloom, S. Gurram, M. Siddiqui, P. Pinsky, H. Parnes, W. M. Linehan, M. Merino, P. L. Choyke, J. H. Shih, B. Turkbey, B. J. Wood, and P. A. Pinto, “Mri-targeted, systematic, and combined biopsy for prostate cancer diagnosis,” *New England Journal of Medicine*, vol. 382,

- pp. 917–928, 3 2020. [Online]. Available: <https://www.nejm.org/doi/full/10.1056/NEJMoa1910038>
- [8] O. Morozova and M. A. Marra, “Applications of next-generation sequencing technologies in functional genomics,” *Genomics*, vol. 92, pp. 255–264, 11 2008. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/18703132/>
- [9] S. Ikeda, S. K. Elkin, B. N. Tomson, J. L. Carter, and R. Kurzrock, “Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing,” *Cancer Biology & Therapy*, vol. 20, pp. 219–226, 2 2019. [Online]. Available: <https://www.tandfonline.com/doi/abs/10.1080/15384047.2018.1523849>
- [10] R. Ibrahim, N. A. Yousri, M. A. Ismail, and N. M. El-Makky, “Mirna and gene expression based cancer classification using self-learning and co-training approaches,” *Proceedings - 2013 IEEE International Conference on Bioinformatics and Biomedicine, IEEE BIBM 2013*, pp. 495–498, 2013.
- [11] M. F. Kabir and S. A. Ludwig, “Classification models and survival analysis for prostate cancer using rna sequencing and clinical data,” *Proceedings - 2019 IEEE International Conference on Big Data, Big Data 2019*, pp. 2736–2745, 12 2019.
- [12] M. Casey, B. Chen, J. Zhou, and N. Zhou, “A machine learning approach to prostate cancer risk classification through use of rna sequencing data,” *Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)*, vol. 11514 LNCS, pp. 65–79, 2019. [Online]. Available: [https://link.springer.com/chapter/10.1007/978-3-030-23551-2\\_5](https://link.springer.com/chapter/10.1007/978-3-030-23551-2_5)
- [13] S. Singh, A. K. Pathak, S. Kural, L. Kumar, M. G. Bhardwaj, M. Yadav, S. Trivedi, P. Das, M. Gupta, and G. Jain, “mirna biomarkers in prostate cancer: Leveraging machine learning for improved diagnostic accuracy,” 10 2024. [Online]. Available: <http://biorxiv.org/lookup/doi/10.1101/2024.10.25.618146>
- [14] “Prostate cancer stages — staging of prostate cancer — american cancer society.” [Online]. Available: <https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/staging.html>
- [15] K. P. Singh, C. Miaskowski, A. A. Dhruva, E. Flowers, and K. M. Kober, “Mechanisms and measurement of changes in gene expression,” *Biological Research for Nursing*, vol. 20, p. 369, 7 2018. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6346310/>

- [16] Z. Akond, M. Alam, and M. N. H. Mollah, “Biomarker identification from rna-seq data using a robust statistical approach,” *Bioinformation*, vol. 14, p. 153, 4 2018. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6016759/>
- [17] F. Finotello and B. D. Camillo, “Measuring differential gene expression with rna-seq: Challenges and strategies for data analysis,” *Briefings in Functional Genomics*, vol. 14, pp. 130–142, 3 2015. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/25240000/>
- [18] K. Sundarbose, R. V. Kartha, and S. Subramanian, “Micrornas as biomarkers in cancer,” *Diagnostics*, vol. 3, p. 84, 2013. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4665585/>
- [19] H. Wang, R. Peng, J. Wang, Z. Qin, and L. Xue, “Circulating micrornas as potential cancer biomarkers: The advantage and disadvantage,” *Clinical Epigenetics*, vol. 10, pp. 1–10, 4 2018. [Online]. Available: <https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-018-0492-1>
- [20] D. Rosati, M. Palmieri, G. Brunelli, A. Morrione, F. Iannelli, E. Frullanti, and A. Giordano, “Differential gene expression analysis pipelines and bioinformatic tools for the identification of specific biomarkers: A review,” *Computational and Structural Biotechnology Journal*, vol. 23, p. 1154, 12 2024. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10951429/>
- [21] M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, and G. K. Smyth, “limma powers differential expression analyses for rna-sequencing and microarray studies,” *Nucleic Acids Research*, vol. 43, pp. e47–e47, 4 2015. [Online]. Available: <https://dx.doi.org/10.1093/nar/gkv007>
- [22] A. M. Priyatno and T. Widiyaningtyas, “A systematic literature review: Recursive feature elimination algorithms,” *JITK (Jurnal Ilmu Pengetahuan dan Teknologi Komputer)*, vol. 9, pp. 196–207, 2 2024.
- [23] P. M. Granitto, C. Furlanello, F. Biasioli, and F. Gasperi, “Recursive feature elimination with random forest for ptr-ms analysis of agroindustrial products,” *Chemometrics and Intelligent Laboratory Systems*, vol. 83, pp. 83–90, 9 2006. [Online]. Available: <https://www.sciencedirect.com/science/article/abs/pii/S0169743906000232>
- [24] “Rfe — scikit-learn 1.7.1 documentation.” [Online]. Available: [https://scikit-learn.org/stable/modules/generated/sklearn.feature\\_selection.RFE.html](https://scikit-learn.org/stable/modules/generated/sklearn.feature_selection.RFE.html)
- [25] D. G. Kleinbaum and M. Klein, “Logistic regression,” 2010. [Online]. Available: <http://link.springer.com/10.1007/978-1-4419-1742-3>

- [26] X. Zou, Y. Hu, Z. Tian, and K. Shen, “Logistic regression model optimization and case analysis,” *Proceedings of IEEE 7th International Conference on Computer Science and Network Technology, ICCSNT 2019*, pp. 135–139, 10 2019.
- [27] S. Handoyo, Y. P. Chen, G. Irianto, and A. Widodo, “The varying threshold values of logistic regression and linear discriminant for classifying fraudulent firm,” *Mathematics and Statistics*, vol. 9, pp. 135–143, 2021.
- [28] J. Qin and Y. Lou, “L1-2 regularized logistic regression,” *Conference Record - Asilomar Conference on Signals, Systems and Computers*, vol. 2019-November, pp. 779–783, 11 2019.
- [29] “Logisticregression — scikit-learn 1.7.1 documentation.” [Online]. Available: [https://scikit-learn.org/stable/modules/generated/sklearn.linear\\_model.LogisticRegression.html](https://scikit-learn.org/stable/modules/generated/sklearn.linear_model.LogisticRegression.html)
- [30] L. Breiman, “Random forests,” *Machine Learning*, vol. 45, pp. 5–32, 10 2001. [Online]. Available: <https://link.springer.com/article/10.1023/A:1010933404324>
- [31] V. Jackins, S. Vimal, M. Kaliappan, and M. Y. Lee, “Ai-based smart prediction of clinical disease using random forest classifier and naive bayes,” *Journal of Supercomputing*, vol. 77, pp. 5198–5219, 5 2021. [Online]. Available: <https://link.springer.com/article/10.1007/s11227-020-03481-x>
- [32] B. H. Menze, B. M. Kelm, R. Masuch, U. Himmelreich, P. Bachert, W. Petrich, and F. A. Hamprecht, “A comparison of random forest and its gini importance with standard chemometric methods for the feature selection and classification of spectral data,” *BMC Bioinformatics*, vol. 10, pp. 1–16, 7 2009. [Online]. Available: <https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-10-213>
- [33] “Randomforestclassifier — scikit-learn 1.7.1 documentation.” [Online]. Available: <https://scikit-learn.org/stable/modules/generated/sklearn.ensemble.RandomForestClassifier.html>
- [34] M. Grandini, E. Bagli, and G. Visani, “Metrics for multi-class classification: an overview,” 8 2020. [Online]. Available: <https://arxiv.org/pdf/2008.05756.pdf>
- [35] T. Fawcett, “An introduction to roc analysis,” *Pattern Recognition Letters*, vol. 27, pp. 861–874, 6 2006. [Online]. Available: <https://www.sciencedirect.com/science/article/pii/S016786550500303X>
- [36] Şeref Kerem Çorbacıoğlu and G. Aksel, “Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value,” *Turkish Journal of Emergency Medicine*, vol. 23, pp.

- 195–198, 10 2023. [Online]. Available: <https://www.scribd.com/document/744381708/Guide-to-interprate-ROC-Analysis>
- [37] “Ucsc xena.” [Online]. Available: [https://xenabrowser.net/datapages/?cohort=GDC%20TCGA%20Prostate%20Cancer%20\(PRAD\)&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443](https://xenabrowser.net/datapages/?cohort=GDC%20TCGA%20Prostate%20Cancer%20(PRAD)&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443)
- [38] Genomics BioTools, “Ensembl id to gene symbol converter,” [Online]. Available: [https://biotools.fr/human/ensembl\\_symbol\\_converter](https://biotools.fr/human/ensembl_symbol_converter), 2025.
- [39] N. Shajari, S. Davudian, T. Kazemi, B. Mansoori, S. Salehi, V. K. Shahgoli, D. Shanehbandi, A. Mohammadi, P. H. G. Duijf, and B. Baradaran, “Silencing of *bach1* inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression,” *Artificial Cells, Nanomedicine and Biotechnology*, vol. 46, pp. 1495–1504, 10 2018. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/28889753/>
- [40] R. L. Mather, A. Parolia, S. E. Carson, E. Venalainen, D. Roig-Carles, M. Jaber, S. C. Chu, I. Alborelli, R. Wu, D. Lin, N. Nabavi, E. Jachetti, M. P. Colombo, H. Xue, P. Pucci, X. Ci, C. Hawkes, Y. Li, H. Pandha, I. Ulitsky, C. Marconett, L. Quagliata, W. Jiang, I. Romero, Y. Wang, and F. Crea, “The evolutionarily conserved long non-coding rna linc00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms,” *Molecular Oncology*, vol. 15, pp. 1921–1941, 7 2021. [Online]. Available: <https://doi.org/10.1002/1878-0261.12954><https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12954><https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12954>
- [41] S. Han, S. Jang, S. W. Lee, H. Y. Kim, W. Kim, H. G. Kim, J. K. Park, J. E. Han, Z. Y. Ryoo, E. Seah, C. Kim, J. Lee, S. Park, and S. K. Choi, “*hmagea2* accelerates the progression of prostate cancer via the *efna3-erk1/2* signaling pathway,” *Anticancer Research*, vol. 44, pp. 2847–2859, 7 2024. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/38925815/>
- [42] L. Cheng, Z. Qiu, X. Wu, and Z. Dong, “Evaluation of circulating plasma proteins in prostate cancer using mendelian randomization,” *Discover Oncology*, vol. 15, pp. 1–12, 12 2024. [Online]. Available: <https://link.springer.com/article/10.1007/s12672-024-01331-3>
- [43] V. L. da Silva, A. F. Fonseca, M. Fonseca, T. E. da Silva, A. C. Coelho, J. E. Kroll, J. E. S. de Souza, B. Stransky, G. A. de Souza, and S. J. de Souza, “Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis,” *Oncotarget*, vol. 8, p. 92966, 2017. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5696236/>

- [44] W. Wang, T. Li, Z. Xie, J. Zhao, Y. Zhang, Y. Ruan, and B. Han, “Integrating single-cell and bulk rna sequencing data unveils antigen presentation and process-related cafs and establishes a predictive signature in prostate cancer,” *Journal of Translational Medicine*, vol. 22, pp. 1–21, 12 2024. [Online]. Available: <https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04807-y> <http://creativecommons.org/publicdomain/zero/1.0/>
- [45] J. Lv, Y. He, L. Li, and Z. Wang, “Alternative splicing events and splicing factors are prognostic in adrenocortical carcinoma,” *Frontiers in Genetics*, vol. 11, p. 519316, 9 2020. [Online]. Available: [www.frontiersin.org](http://www.frontiersin.org)
- [46] H. Zhang, C. Hao, Y. Wang, S. Ji, X. Zhang, W. Zhang, Q. Zhao, J. Sun, and J. Hao, “Sohlh2 inhibits human ovarian cancer cell invasion and metastasis by transcriptional inactivation of mmp9,” *Molecular Carcinogenesis*, vol. 55, pp. 1127–1137, 7 2016. [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/26153894/>
- [47] Y. Wu, S. Yin, C. Li, L. Zhao, M. Song, Y. Yu, L. Tang, and Y. Yang, “A signature of seven hypoxia-related lncrnas is a potential biomarker for predicting the prognosis of melanoma,” *American Journal of Cancer Research*, vol. 14, p. 1712, 2024. [Online]. Available: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11076246/>

